Enabling global access to high-quality biopharmaceuticals

Current Opinion in Chemical Engineering

Volumn 2, Issue 4, 2013, Pages 383-390

  Love, J Christopher ^a,b   Love, Kerry Routenberg ^a   Barone, Paul W ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROCESS MONITORING;

BIOLOGIC DRUGS; BIOPHARMACEUTICAL INDUSTRY; BIOPHARMACEUTICALS; COST-OF-GOODS; DELIVERY MECHANISM; DRUG DEVELOPMENT; ECONOMIC MODELS; PUBLIC PRIVATE PARTNERSHIPS;

DRUG PRODUCTS;

EID: 84899933397     PISSN: None     EISSN: 22113398     Source Type: Journal    
DOI: 10.1016/j.coche.2013.09.002     Document Type: Review

References (61)

1. Walsh G: Biopharmaceutical benchmarks 2010. Nat Biotechnol 2010, 28:917-924.
2. Aggarwal S: What's fueling the biotech engine-2011 to 2012. Nat Biotechnol 2012, 30:1191-1197.
3. Osborne R: Fresh from the biotech pipeline - 2012. Nat Biotechnol 2013, 31:100-103.
4. McCamish M, Woollett G: Worldwide experience with biosimilar development. MAbs 2011, 3:209-217.
5. Ransohoff T, Ecker D, Levine H, Miller J: Cell culture manufacturing capacity: trends and outlook through 2013. PharmSource 2008:126.
6. Genzyme Corporation Annual Report, (10K), Cambridge, MA; 2010
7. Batson A, Glass S, Seiguer E: Economics of vaccines: from vaccine candidates to commercialized product. In The Vaccine. Edited by Bloom BR., Lambert P-HH.. USA: Elsevier Science; 2003.
8. Moran N: Biotech innovators jump on biosimilars bandwagon. Nat Biotechnol 2012, 30:297-299.
9. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi M: Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011, 378:1461-1484.
10. Chatterjee S, Frenkel E, Gertner G, Glassberg H, Lin A, Mir T, Poynton C, Roland M, Teichman E, Tiede B et al.: Leveraging Public Private Partnerships to Address Global Vaccine Needs: Evaluation of the Merck-Wellcome Trust Hilleman Laboratories. The Woodrow Wilson School's Graduate Policy Workshop Princeton University; 2011.
11. Batson A: The costs and economics of modern vaccine development. Dev Biol (Basel) 2002, 110:15-24.
12. Walsh G: Biopharmaceuticals: Biochemistry and Biotechnology. John Wiley & Sons; 2006.
13. Sinclair A, Monge M: Measuring manufacturing cost and its impact on organizations. BioProcess Int 2010, 8:10-14.
14. Kelley B: Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 2009, 1:443-452.
15. Farid SS: Process economics of industrial monoclonal antibody manufacture. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 848:8-18. (Pubitemid 46367764)
16. Levine HL, Jagschies G: The development of therapeutic monoclonal antibody products. 2010, BioProcess Technology Consultants, In.c.
17. Shaping the Biosimilars Opportunity: A Global Perspective on the Evolving Biosimilars Landscape. IMS Health; 2011.
18. Donninger R, Bower J, Kaiser R, Estdale S, Carlsen J: Key considerations in biosimilars development. Biopharm Int 2012, 25:37-39.
19. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F: The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001, 19:2716-2720.
20. Hamilton SR, Gerngross TU: Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr Opin Biotechnol 2007, 18:387-392. (Pubitemid 350116586)
21. Cox MMJ, Hollister JR: FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 2009, 37:182-189.
22. Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Munoz ET, Solorio-Meza SE, Amato D, Duran G, Giona F et al.: Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011, 118:5767-5773.
23. Drugmand JC, Schneider YJ, Agathos SN: Insect cells as factories for biomanufacturing. Biotechnol Adv 2012, 30:1140-1157.
24. Hou JJC, Codamo J, Pilbrough W, Hughes B, Gray PP, Munro TP: New frontiers in cell line development: challenges for biosimilars. J Chem Technol Biotechnol 2011, 86:895-904.
25. Castilho A, Strasser R, Stadlmann J, Grass J, Jez J, Gattinger P, Kunert R, Quendler H, Pabst M, Leonard R et al.: In planta protein sialylation through overexpression of the respective mammalian pathway. J Biol Chem 2010, 285:15923-21593.
26. Opar A: 'Pharmers' hope for first plant drug harvest. Nat Rev Drug Discov 2011, 10:81-82.
27. Aviezer D, Brill-Almon E, Shaaltiel Y, Hashmueli S, Bartfeld D, Mizrachi S, Liberman Y, Freeman A, Zimran A, Galun E: A plantderived recombinant human glucocerebrosidase enzyme - a preclinical phase I investigation. PLoS ONE 2009, 4:e4792.
28. Li PZ, Anumanthan A, Gao XG, Ilangovan K, Suzara VV, Duzgunes N, Renugopalakrishnan V: Expression of recombinant proteins in Pichia pastoris. Appl Biochem Biotechnol 2007, 142:105-124. (Pubitemid 47557234)
29. Chappelle R: FDA Approves New Seasonal Influenza Vaccine Made Using Novel Technology. US Food and Drug Administration; 2013.
30. Cox MMJ: Recombinant protein vaccines produced in insect cells. Vaccine 2012, 30:1759-1766.
31. Larrick JW, Thomas DW: Producing proteins in transgenic plants and animals. Curr Opin Biotechnol 2001, 12:411-418. (Pubitemid 32718797)
32. Mullard A: 2012 FDA drug approvals. Nat Rev Drug Discov 2013, 12:87-90.
33. Low D, O'Leary R, Pujar NS: Future of antibody purification. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 848:48-63. (Pubitemid 46389595)
34. Godawat R, Brower K, Jain S, Konstantinov K, Riske F, Warikoo V: Periodic counter-current chromatography - design and operational considerations for integrated and continuous purification of proteins. Biotechnol J 2012, 7:1496-1508.
35. Warikoo V, Godawat R, Brower K, Jain S, Cummings D, Simons E, Johnson T, Walther J, Yu M, Wright B et al.: Integrated continuous production of recombinant therapeutic proteins. Biotechnol Bioeng 2012, 109:3018-3029.
36. Lee J, Gan HT, Latiff SMA, Chuah C, Lee WY, Yang Y-S, Loo B, Ng SK, Gagnon P: Principles and applications of steric exclusion chromatography. J Chromatogr A 2012, 1270:162-170.
37. Gagnon P: Steric exclusion chromatography. Gen EngBiotechnol News 2013:33.
38. Becker T, Lawlis VBJ: Subtilisin crystallization process. US Patent 1991.
39. Przybycien TM, Pujar NS, Steele LM: Alternative bioseparation operations: life beyond packed-bed chromatography. Curr Opin Biotechnol 2004, 15:469-478. (Pubitemid 39310505)
40. Thommes J, Etzel M: Alternatives to chromatographic separations. Biotechnol Prog 2007, 23:42-45. (Pubitemid 46293484)
41. Flores H, Lin T, Matthews T, Pai R, Shahrokh Z: Method of purifying APO-2 ligand/TRAIL using crystallization the cold. US Patent, US 2011/0054153 A1.
42. Trilisky E, Gillespie R, Osslund TD, Vunnum S: Crystallization and liquid-liquid phase separation of monoclonal antibodies and Fc-fusion proteins: screening results. Biotechnol Prog 2011, 27:1054-1067.
43. Zang Y, Kammerer B, Eisenkolb M, Lohr K, Kiefer H: Towards protein crystallization as a process step in downstream processing of therapeutic antibodies: screening and optimization at microbatch scale. PLoS ONE 2011:6.
44. Handlogten MW, Stefanick JF, Alves NJ, Bilgicer B: Nonchromatographic affinity precipitation method for the purification of bivalently active pharmaceutical antibodies from biological fluids. Anal Chem 2013, 85:5271-5278.
45. Liu LM, Li HJ, Hamilton SR, Gomathinayagam S, Rayfield WJ, Van Maanen M, Yin KC, Hong L, Prueksaritanont T: The impact of sialic acids on the pharmacokinetics of a PEGylated erythropoietin. J Pharm Sci 2012, 101:4414-4418.
46. Li HJ, Sethuraman N, Stadheim TA, Zha DX, Prinz B, Ballew N, Bobrowicz P, Choi BK, Cook WJ, Cukan M et al.: Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 2006, 24:210-215. (Pubitemid 43221706)
47. Jacobs PP, Geysens S, Vervecken W, Contreras R, Callewaert N: Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology. Nat Protocols 2009, 4:58-70.
48. Liu LM, Gomathinayagam S, Hamuro L, Prueksaritanont T, Wang WR, Stadheim TA, Hamilton SR: The impact of glycosylation on the pharmacokinetics of a TNFR2:Fc fusion protein expressed in glycoengineered Pichia pastoris. Pharm Res 2013, 30:803-812.
49. Castilho A, Neumann L, Daskalova S, Mason HS, Steinkellner H, Altmann F, Strasser R: Engineering of sialylated mucin-type Oglycosylation in plants. J Biol Chem 2012, 287:36518-36526.
50. Beutel S, Henkel S: In situ sensor techniques in modern bioprocess monitoring. Appl Microbiol Biotechnol 2011, 91:1493-1505.
51. Lee HLT, Boccazzi P, Gorret N, Ram RJ, Sinskey AJ: In situ bioprocess monitoring of Escherichia coli bioreactions using Raman spectroscopy. Vib Spectroscop 2004, 35:131-137.
52. Abu-Absi NR, Kenty BM, Cuellar ME, Borys MC, Sakhamuri S, Strachan DJ, Hausladen MC, Li ZJ: Real time monitoring of multiple parameters in mammalian cell culture bioreactors using an in-line Raman spectroscopy probe. Biotechnol Bioeng 2011, 108:1215-1221.
53. Kuebler S: Characterizing stable protein formulations. Gen Eng Biotechnol News 2007:27.
54. Nagaraj VJ, Aithal S, Eaton S, Bothara M, Wiktor P, Prasad S: NanoMonitor: a miniature electronic biosensor for glycan biomarker detection. Nanomedicine (Lond) 2010, 5:369-378.
55. Reuel NF, Ahn JH, Kim JH, Zhang J, Boghossian AA, Mahal LK, Strano MS: Transduction of glycan-lectin binding using nearinfrared fluorescent single-walled carbon nanotubes for glycan profiling. J Am Chem Soc 2011, 133:17923-17933.
56. Fu J, Mao P, Han J.: Artificial molecular sieves and filters: a new paradigm for biomolecule separation. Trends Biotechnol 2008, 26:311-320.
57. Fu J, Mao P, Han J: Continuous-flow bioseparation using microfabricated anisotropic nanofluidic sieving structures. Nat Protocols 2009, 4:1681-1698.
58. Cohen J: AIDS research More woes for struggling HIV vaccine field. Science 2013, 340:667.
59. Chen W, Ying T, Dimitrov DS: Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design. Expert Opin Biol Ther 2013, 13:657-671.
60. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR: Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009, 15:951-954.
61. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A et al.: HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012, 492:118-122.